Publications
2024
Howard FM, Hieromnimon HM, Ramesh S, Dolezal J, Kochanny S, Zhang Q, Brad Feiger, Peterson J, Fan C, Perou CM, Vickery J, Sullivan M, Cole K, Khramtsova G, Pearson A. Generative Adversarial Networks Accurately Reconstruct Pan-Cancer Histology from Pathologic, Genomic, and Radiographic Latent Features. bioRxiv. 2024 March 25. doi: 10.1101/2024.03.22.586306.
2023
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441. Epub ahead of print. PMID: 37721526.
Dolezal JM, Wolk R, Hieromnimon HM, Howard FM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Kwon JW, Agni M, Simon RC, Desai C, Kherallah R, Nguyen TD, Schulte JJ, Cole K, Khramtsova G, Garassino MC, Husain AN, Li H, Grossman R, Cipriani NA, Pearson AT. Deep learning generates synthetic cancer histology for explainability and education. npj Precis. Onc. 7, 49 (2023). https://doi.org/10.1038/s41698-023-00399-4
Hieromnimon HM, Dolezal J, Doytcheva K, Howard FM, Kochanny S, Zhang Z, Grossman RL, Tanager K, Wang C, Kather JN, Izumchenko E, Cipriani NA, Fertig EJ, Pearson AT, Riesenfeld SJ. Latent transcriptional programs reveal histology-encoded tumor features spanning tissue origins. bioRxiv 2023.03.22.533810; doi: https://doi.org/10.1101/2023.03.22.533810
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, El-Aryani G, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Sykes D, Swarbrick A, Schürer S, Patnaik A. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. Clin Cancer Res CCR-22-3350, (2023). https://doi.org/10.1158/1078-0432.CCR-22-3350
2022
Hieromnimon, HM, Pearson, AT. Ovarian cancer through a multi-modal lens. Nat Cancer 3, 662–664 (2022). https://doi.org/10.1038/s43018-022-00397-8
2021
Chaudagar KK, Landon-Brace N, Solanki A, Hieromnimon HM, Hegermiller E, Li W, Shao Y, Joseph J, Wilkins DJ, Bynoe KM, Li XL, Clohessy JG, Ullas S, Karp JM, Patnaik A. Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. Mol Cancer Ther. 2021 Feb;20(2):438-449. doi: 10.1158/1535-7163.MCT-20-0167. Epub 2020 Dec 4. PMID: 33277441.
Abstracts
2023
Chaudagar, K; Hieromnimon, HM.; Kelley, A; Labadie, B; Shafran, J; Rameshbabu, S; et al. (2023). Data from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. American Association for Cancer Research. Collection. https://doi.org/10.1158/1078-0432.c.6960647.v1
2020
Patnaik A, Duttagupta P, Chaudagar K, Alter R, Hieromnimon HM, Szmulewitz RZ, Fleming GF, Stadler WM. A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology 2020 38:6_suppl, TPS270-TPS270
